Functional Characterization
Investigating recurrent cancer mutations identified through our clinical diagnostic service. We utilize mammary-specific mutant GATA3 mouse models and in vitro BRAF characterization to explain how genetic alterations drive cancer initiation.
Triple-Negative Breast Cancer
Addressing aggressive diseases lacking ER, PR, and HER2 expression. Our goal is to validate novel therapeutic targets for TNBC, which disproportionately affects younger women and requires specialized intervention.
Mammary Gland Development
Studying development-regulating genes and their impact on future tumor risk. Our research highlights the EGFR ligand, Amphiregulin, and its critical role in p53-dependent tumor progression.
Resistance Mechanisms
Performing longitudinal sequencing on patient specimens to decode acquired resistance to MET, ROS1, and BRAF inhibition, as well as checkpoint immunotherapies in lung cancer and melanoma.